Paradigm Biopharmaceuticals Limited

A$0.24As of Sun 8 Nov 2026, 12:00 UTC
ASX:PARHealthcare
Country Australia
PE (Fwd) •••
TSR 10Y CAGR (6.13%)
Div yield —
ROE (456.96%)
Biotechnology
Beta (5Y) 0.05
PE TTM —
TSR TTM (42.35%)
Mkt cap A$153.5M
ROIC (237.77%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.236
(3.47%)
(59.85%)
Buy 10|6|6|1|11
2Q26
3Q26
4Q26
1Q27
Earnings per share$
0.01
0.01
0.01
0.01
17.77%
18.27%
13.82%
10.21%
Revenue$M
9.370
9.844
9.596
10.03
4.83%
6.19%
3.80%
7.78%
Peers (US$105.4M)
Cap (US$)
PE
107.6M
—
Capital
TTM
5Y
10Y
Leveragex
0.730
(0.097)
(0.093)
EBIT/Intx
3.489
0.124
0.139
Own earn%
286.12
(19.71)
(29.10)
Sh yield%
22.25
44.80
45.70
Owners
Insiders/Inst%
11.04
21.85
Short interest%
1.94
SBC / revenue%
5.61
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
4–13
$1 testx
0.0
Incr. ROIC%
1